Compare iShares Self-Driving EV and Tech (IDRV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Novo Nordisk A/S — how do they compare? iShares Self-Driving EV and Tech trades at $35.9, while Novo Nordisk A/S trades at $49.37 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares Self-Driving EV and Tech pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $71.70 |
52-Week Low | $32.13 | $35.29 |
Market Cap | — | $220.53B |
Enterprise Value | — | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.
The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
